MedTrace Logo

UCB Cimzia Pregnancy Follow-up Study

NCT02775656 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2021-04-22

No results posted yet for this study

Summary

The purpose of this observational follow-up study is to collect data systematically on pregnancies and offspring of women who become pregnant while participating in a Certolizumab Pegol (CZP) study or whose pregnancies have otherwise been reported to UCB due to potential CZP exposure during pregnancy.

Conditions

  • Rheumatoid Arthritis (RA)
  • Crohn's Disease (CD)
  • Psoriatic Arthritis (PsA)
  • Axial Spondyloarthritis and Ankylosing Spondylitis

Sponsors & Collaborators

  • Syneos Health

    collaborator OTHER

  • Parexel

    collaborator INDUSTRY

  • UCB BIOSCIENCES, Inc.

    lead INDUSTRY

Principal Investigators

  • UCB Cares · UCB Pharma

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02775656 on ClinicalTrials.gov